Unaudited Standalone & consolidated Financial Result of the company for the quarter & half year ended 30th September 2026.

GENPHARMASEC LIMITED Date: 03.11.2026 BSE Limited The Compliance Department of Corporate Services, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001. Scrip Code: 531592 Subject: Outcome of the Meeting of Board of Directors held on Tuesday, 03'4 November, 2026. Dear Sir/Madam, With reference to the captioned subject and Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Directors of the Company at its meeting held on today, i.e Tuesday, 034 November, 2026, have inter alia, other matters: 1. Considered and approved the Un-audited Standalone & Consolidated Financial Results of the Company along with Limited Review Report of the Statutory Auditor for the quarter and half year ended September 30, 2026. 2. Considered and approved the Disinvestment/Sale/Disposal of entire Equity stake held in its wholly owned subsidiary company viz., Clinigenome India Private Limited. Clinigenome India Private Limited is not a material subsidiary of the company. Upon Completion of the aforesaid sale, Clinigenome India Private Limited will cease to be a wholly owned subsidiary of the Company. Details as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3/7206226 dated January 30, 2026, is enclosed as Annexure-A. 3. Considered and approved the Resignation of Mr. Hardik Makwana, Company Secretary and Compliance Officer of the Company, from his position with effect from close of business hours on November 16, 2026. (a copy of the resignation letter is attached herewith). Details as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3/7206226 dated January 30, 2026, is enclosed as Annexure-B. 104 & 105, 1st Floor, Gundecha Industrial Premises Co-Operative Soc compliance@genpharmasec.com Ltd., Akurli Road, Kandivali (East), Mumbai 400101. info@genpharmasec.com © +91-86555 50242 a www.genpharmasec.com CIN : L24231MH1992PLC323914 GENPHARMASEC LIMITED We further inform you that the Board Meeting commenced at 04:30 p.m. today and concluded at 05:15 p.m. Kindly take the same on records for your perusal. Thanking you, Yours faithfully, For Genpharmasec Limited Digitally signed by SOHAN SOHAN CHATURVEDI CHATURVEDI ri 51 +0830 Mr. Sohan Chaturvedi Whole time director & CFO DIN- 09629728 Encl: 1. Un-Audited Standalone & Consolidated Financial Results for the quarter & half year ended September 30, 2026. 2. Limited Review Report of the Auditor. 3. Resignation letter. 104 & 105, 1st Floor, Gundecha Industrial Premises Co-Operative Soc compliance@genpharmasec.com Ltd., Akurli Road, Kandivali ( East), Mumbai 400101. info@genpharmasec.com © +91-86555 50242 a www.genpharmasec.com CIN : L24231MH1992PLC323914 GENPHARMASEC LIMITED Annexure-A Sr No. Particulars Details 1. The amount and percentage of turnove r\Name of the subsidiary: lor revenue or income and net worth!Clinigenome India Private Limited contributed by such unit or division of undertaking or subsidiary or associate s ticulars Rs. In La khs % company of the listed entity during the last financial year. 0.72 % of the (Turnover 100.47 consolidated turnover 2.35% of the Net Worth (154.41) consolidated turnover 2. (Date on which the agreement for sal eYet to be entered. Ilhas been entered. (The Company will intimate the Exchanges upon signing of agreement. 3. The expected date of completion offfhe proposed sale transaction is expected to sale / disposal. ibe completed on or before March 31, 2027, or such other date as may be determined and approved by the Board of Directors of the Company. 4. |Consideration received from _ such lThe consideration for the proposed sale shall sale / disposal. Ibe such amount as may be determined, negotiated and approved by the Board of Directors of the Company. 5. [Brief details of Buyers and whether an yjThe Board of Directors of the Company has| of the buyers belong to the Promoter oridentified Micro Genomics India Private the Promoter Group/ Group|Limited as the proposed buyer for the sale. Companies. If yes, details thereof. [The proposed buyer does not belong to the Promoter or Promoter Group or Group Companies of the Company. 6. |Whether the transaction would fa lllNot Applicable within related party transactions? If lyes, whether the same is done at arm’s length. 7. [Whether the sale, lease or disposal offNot Applicable the undertaking is outside the Scheme of Arrangement? If yes, details of the Same including Compliance under regulation 37 A of the LODR Regulations. 8. |Additionally, in case of a slump sale ,/Not Applicable indicative disclosures provided for amalgamation /merger, shall be disclosed by the listed entity with respect to such slump sale. 104 & 105, 1st Floor, Gundecha Industrial Premises Co-Operative Soc compliance@genpharmasec.com Ltd., Akurli Road, Kandivali (East), Mumbai 400101. info@genpharmasec.com @®) +91-86555 50242 a www.genpharmasec.com CIN : L24231MH1992PLC323914 GENPHARMASEC LIMITED Annexure-B Sr. No. Particulars Details 1. Reason for change viz. | Resignation Due to pursue of other appeintment, re-appointment, | professional opportunities outside the resignation, remeval, death or | Organization. etherwise; 2. Date of | Cessation with effective from the close of appeintment/reappeintment/cessa | Business hours on November 16, 2026. tion (as applicable) & term—ef 3. Brief — Profile (in case of | Not Applicable appointment); 4. Disclosure of Relationships | Not Applicable between Directors (in case of appointment of a director); 104 & 105, 1st Floor, Gundecha Industrial Premises Co-Operative Soc compliance@genpharmasec.com Ltd., Akurli Road, Kandivali (East), Mumbai 400101. info@genpharmasec.com @®) +91-86555 50242 a www.genpharmasec.com CIN : L24231MH1992PLC323914 BILIMORIA MEHTA & CO. CHARTERED ACCOUNTANTS Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended The Board of Directors of Genpharmasec Limited 1. We have reviewed the accompanying statement of unaudited standalone financial results (‘the Statement') of Genpharmasec Limited (‘the Company') for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 attached herewith being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. 2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (‘Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for fin [Showing first 8,000 characters — download PDF for full document]